Macquarie Group
IRLA

Macquarie Group’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Macquarie Group’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed -$3K – 2617
2022
Q1 		$3K Hold
2
– – ﹤0.01% 2606
2021
Q4 		$6K Hold
2
– – ﹤0.01% 2563
2021
Q3 		$40K Hold
2
– – ﹤0.01% 2293
2021
Q2 		$23K Hold
2
– – ﹤0.01% 2340
2021
Q1 		$16K Sell
2
-1
-33% -$7.2K ﹤0.01% 2327
2020
Q4 		$16K Hold
3
– – ﹤0.01% 2255
2020
Q3 		$29K Hold
3
– – ﹤0.01% 2083
2020
Q2 		$27K Buy
+3
New +$27.5K ﹤0.01% 2089

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Macquarie Group's IRLA Position: Q2 2022 in Review

Macquarie Group sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 2 shares — an estimated $3K sold.

Macquarie Group first reported a position in IRLA in Q2 2020 and held it in 8 quarters. The position peaked at $40K in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

  • Macquarie Group reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Macquarie Group sold 2 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $3K.
  • Macquarie Group first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2020 and held it in 8 quarters.
  • Macquarie Group's IRulya Therapeutics Inc. Common Stock position peaked at $40K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on Macquarie Group's 13F filing for Q2 2022, filed 15 Aug 2022.